Uromitexan (Farmitalia Carlo Erba)
100 mg/mL in 2 mL, 4 mL and 10 mL single dose ampoules
Indication: prevention and reduction of urothelial toxicity
Alkylating agents such as cyclophosphamide and ifosfamide can cause haemorrhagic cystitis. Mesna can reduce this toxicity as it reacts with the metabolites which cause the adverse effects on the urothelium.
The drug is given intravenously at the same time as the alkylating agent and is then repeated after 4 and 8 hours. It is eliminated rapidly from the plasma and the majority of the dose is excreted renally within 4 hours.
As mesna is usually given with potent anticancer drugs, it is difficult to attribute adverse effects. Mesna may be associated with diarrhoea, headache and altered taste.